Dr. Kulkarni’s research focuses on the intersection of basic biology, technology, and medicine to help better realize the vision of personalized medicine in cancer.  His research is focused on basic and translational studies to enable molecularly-based, personalized approaches to cancer care, in collaboration with the VA, the Center for Early Detection Research (CEDAR), and the Knight Cancer Institute (KCI).  A parallel line of research focuses on oncodermatology and elucidating the mechanisms by which novel chemotherapeutics and immunotherapies cause skin toxicities/rashes and whether these mechanisms have any correlation with anti-tumor effect and overall outcome. The overall goal is to couple genomic, epigenetic, and clinical information to design novel treatment strategies and ultimately improve patient outcomes.

In his spare time, Dr. Kulkarni enjoys spending time with his family and son. He enjoys exploring the great outdoors, both in the Portland area and throughout the Pacific Northwest.